Homoharringtonine targets XPC to inhibit DNA damage repair and sensitize tumors to platinum-based chemotherapy
In the authors' words
DNA damage repair (DDR) is essential for preserving genomic stability and also represents a key targetable axis in cancer drug development. Here, we identify and validate homoharringtonine (HHT), a clinically approved antileukemic drug, as a novel DDR inhibitor using a phenotype-driven, high-content screen based on 53BP1 Tudor-domain foci formation. Mechanistically, HHT directly binds XPC, a critical nucleotide excision repair (NER) factor, with high affinity (Kd = 158.4 nM) in a manner dependent on Thr795 of XPC. HHT disrupts XPC-damaged DNA binding, impairs NER, and reduces non-homologous end joining (NHEJ) efficiency. Consequently, HHT sensitizes tumor cells to platinum-based chemotherapy in vitro and in vivo. These findings establish a phenotype-based platform for DDR inhibitor discovery, identify HHT as a first-in-class XPC inhibitor and uncover a previously unrecognized mechanism of HHT that may be exploited to enhance platinum-based therapy in solid tumors.
In plain words AI summary
Researchers found that homoharringtonine, an existing leukemia drug, blocks DNA damage repair. The drug binds tightly to a protein called XPC, which cells need to fix damaged DNA. This binding prevents XPC from attaching to damaged DNA and weakens two major repair pathways. As a result, tumor cells become more vulnerable to platinum-based chemotherapy in lab and animal tests. The authors suggest this previously unknown effect could help improve platinum therapy for solid tumors.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Monday, November 2. bioRxiv. Preprint, not yet peer-reviewed.